Vividion Appoints Catherine Friedman to Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- Vividion Therapeutics, Inc.., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Catherine Friedman, a financial industry expert with nearly 40 years of financial industry experience, has been appointed to the company’s board of directors.
“Cathy is a remarkable financial leader who has an extensive wealth of knowledge and experience from a deep career in the healthcare industry,” said Jeffrey Hatfield, chief executive officer of Vividion. “Cathy’s combined history in investment banking, along with the board roles she has held within the biotech industry over the last 15 years, brings a unique and valuable perspective to our growing company. We are thrilled to welcome her to our team, particularly as we advance our lead programs toward clinical development.”
“Vividion has a one-of-a-kind opportunity to address an untapped area of drug development with a pipeline of programs aimed at treating a wide range of underserved cancer and immunology indications,” said Ms. Friedman. “I am excited to partner with this distinguished team and to support their continued evolution as they work to bring their programs into the clinic and, ultimately, deliver them to patients.”
Ms. Friedman is an independent financial consultant who has been serving public and private companies in the life sciences industry since 2006. Previously, Ms. Friedman held numerous executive positions during a 23-year investment banking career with Morgan Stanley, including managing director, and head of West Coast Healthcare, and co-head of the Biotechnology Practice. Ms. Friedman is the chair of the board of directors for GRAIL, Inc. and also serves as a member of the boards of Altaba Inc. (formerly Yahoo! Inc.), Radius Health and Lyell Immunopharma, Inc. She is a trustee of The Darden School Foundation at the University of Virginia. Ms. Friedman holds a B.A. in economics from Harvard University and an MBA from The University of Virginia’s Darden School of Business.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. For more information, please visit www.vividion.com.
THRUST Strategic Communications
Source: Vividion Therapeutics, Inc.